A policy case study of blood in Australia

Social Science and Medicine

Volumn 71, Issue 9, 2010, Pages 1677-1682

  Graves, Nicholas ^a   Clare, Gina ^b   Haines, Mary ^c   Bird, Robert ^d  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b Queensland Health ^*  (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Australia; Blood; Cost effectiveness; Decision making; Efficiency; HIV

Indexed keywords

BLOOD; DECISION MAKING; ECONOMIC ANALYSIS; EFFICIENCY MEASUREMENT; HEALTH CARE; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; MEDICINE; POLICY ANALYSIS;

ARTICLE; AUSTRALIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE PREDISPOSITION; GOVERNMENT; HEALTH CARE; HEALTH CARE COST; LEUKOCYTE; LEUKOPENIA; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; POLICY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SURVIVAL RATE;

AUSTRALIA; COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH POLICY; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; ORGANIZATIONAL CASE STUDIES; POLICY MAKING; POLITICS;

AUSTRALIA;

EID: 77957691384     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.07.035     Document Type: Article

References (26)

1. Alcorta I., Pereira A., Ordinas A. Clinical and laboratory factors associated with platelet transfusion: a case-control study. British Journal of Haematology 1996, 93:220-224.
2. Cooper N.J., Coyle D., Abrams K.R., Mugford M., Sutton A.J. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. Journal of Health Services Research & Policy 2005, 10(4):245-250.
3. Coyle D., Lee K.M. Evidence-based economic evaluation; how the use of different data sources can impact results. Evidence based Health Economics; from effectiveness to efficiency in systematic review 2002, 55-66. BMJ Publishing Group, London. C. Donaldson, M. Mugford, L. Vale (Eds.).
4. Dalziel K., Segal L., Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness?. Cost Effectiveness & Resource Allocation 2008, 6:9.
5. Giandomenico M. Evidence, argument, and persuasion in the policy process. New Haven 1989, Yale University Press, London.
6. Graves N., Halton K., Curtis M., Doidge S., Lairson D., McLaws M., et al. Costs of surgical site infections that appear after hospital discharge. Emerging Infectious Diseases 2006, 12(5):831-834.
7. Graves N., Halton K., Paterson D., Whitby M. Economic rationale for infection control in Australian hospitals. Healthcare Infection 2009, 14:81-88.
8. Graves N., Weinhold D., Tong E., Birrell F., Doidge S., Ramritu P., et al. Effect of healthcare-acquired infection on length of hospital stay and cost. Infection Control & Hospital Epidemiology 2007, 28:280-292.
9. Greenhalgh T., Russell J. Reframing evidence synthesis as rhetorical action in the policy making drama. Healthcare Policy 2005, 1(1):31-39.
10. Gregori L., McCombie N., Palmer D., Birch P. Effectiveness of removal of infectivity of transmissible spongiform encephalopathies from blood. The Lancet 2004, 364(7):529-531.
11. Kingdon J.W. Agendas, alternatives and public policies 1984, Little, Brown, Boston, MA.
12. Krupnick A.J. Valuing health outcomes: policy choices and technical issues 2004, Resources for the Future, Washington.
13. Layard R.N., Glaister S. Introduction. Cost-benefit analysis 1994, 1-56. Cambridge Publishing, London. R. Layard, S. Glaister (Eds.).
14. Lowe J., Bonevski B. Universal leucodepletion of fresh blood products: A report, comprising: Systematic review, stakeholder interviews, economic analysis, summary and recommendations 2001, Hunter Area Health Service & The University of Newcastle, Newcastle, NSW.
15. Rawlins M.D., Culyer A.J. National Institute for clinical excellence and its value judgments. British Medical Journal 2004, 329:224-227.
16. Recuerda Girela, M.A. (2006). Risk and Reason in the European Union Law. European Food and Feed Law Review, 5.
17. Redman S., Jorm L., Haines M. Increasing the use of research in health policy: the Sax Institute model. Australasian Epidemiologist 2008, 15(3):15-18.
18. Sculpher M.J., Claxton K., Drummond M., McCabe C. Whither trial-based economic evaluation for health care decision making?. Health Economics 2006, 15(7):677-687.
19. Shiroiwa T., Sung Y.K., Fukuda T., Lang H.C., Bae S.C., Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Economics 2010, 19:422-437.
20. Spiegelhalter D.J., Abrams K.R., Myles J.P. Bayesian approaches to clinical trials and health-care evaluation 2004, John Wiley & Sons Inc, Chicester.
21. Starr D. Blood: An epic history of medicine and commerce 1999, Little, Brown And Company, Great Britain.
22. Tasaki T., Ohto H., Sasaki S., Kanno T., Igari T., Hoshi Y. Significance of pre-storage leucoreduction for autologous blood. Vox Sang 2009, 96(3). 226-33. Epub 2008 Dec 5.
23. Trueman P., Drummond M., Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19(6):609-621.
24. Vamvakas E.C. Uses and sources of data on long-term survival after blood transfusion. Transfusion Medicine Reviews 2003, 17(3):194-208.
25. van de Watering L. What has universal leucodepletion given us: evidence from clinical trials?. Vox Sang 2004, 87(Suppl 2):139-142.
26. Weinstein M.C., O'Brien B., Hornberger J., Jackson J., Johannesson M., McCabe C., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value in Health 2003, 6(1):9-17.